Checking the effectiveness of SKYCovione,

the first COVID-19 vaccine in Korea

SKYCovione, South Korea's No.

 

1 COVID-19 vaccine developed by SK Bioscience, has been confirmed to have an additional vaccination effect in the cross-neutralization of the omicron mutation virus (BA.1, BA.5).

 

Korea National Institute of Health (Director Kwon Joon-wook) announced on the 2nd that it has confirmed cross-neutralizing anti-bibody testers for the domestic epidemic omicron mutation virus after additional vaccination with SKYCovione.

 

The National Institute of Health conducted a phase 3 clinical trial sample analysis required for item approval of SKYCovione, the first COVID-19 vaccine in Korea developed by SK Bioscience, and a cross-nutritionalizing ability analysis on delta mutant viruses and omicron mutant viruses (BA.1).

 

This analysis confirmed the extent to which SKYCovione's additional inoculation (3rd inoculation) forms neutralizing antibodies against BA.1 and BA.5 mutant viruses, and is the first result of verifying the possibility of use as an additional inoculation vaccine for SKYCovione.

 

As a result of analyzing a total of five subjects who were additionally vaccinated with SKYCovione, the neutralization increase effect was about 51.9 times on average in BA.1 and about 28.2 times in BA.5 compared to before inoculation.

 

The five target groups of basic vaccinations (1st and 2nd) consisted of four single vaccinations (AstraZeneca, Pfizer, Moderna, and Jansen) and one cross vaccination group (AstraZeneca, Pfizer).

 

When additional vaccinations were given with SKYCovione (third inoculation) after basic vaccinations (1st and 2nd) with mRNA formulations, they showed high neutralization in both early Wuhan and BA.

 

1 and BA.

 

5 mutant viruses.

 

Director Kwon Joon-wook said, "SKYCovione was born as the first COVID-19 vaccine in Korea through the support of the analysis of clinical trial samples by the Korea National Institute of Health and the International Vacine Institute." He said, "We confirmed the possibility of using additional vaccinations in Korea through mutation analysis on this additional vaccination group in the situation where mutant viruses such as BA.5 continue to occur." Director Jang Hee-chang said, "In the future, we will continue to support domestic development vaccines such as mRNA vaccines and virus transporter vaccines, such as clinical trial sample analysis and mutation virus evaluation."